The new survey suggests that the injections of weight loss, also known as the GLP-1 receptor agonists, may have a significant impact against cancer beyond simply helping reduce weight.
While experts recognize the link between weight loss and reduced cancer risk, this study indicates the injections itself can play a more direct role.
Researchers believe that real estate against cancer can arise from drug abilities to reduce inflammation, with a receptive GLP-1 agonist receptor that potentially had the most obvious effect. These medications work by suppressing appetite, which facilitates individuals to lose weight. They are available through NHS for those with high BMI and can be obtained privately.
However, experts are cautious that further research is key to fully understand the relationship between the injections of weight loss and cancer prevention.
The main names of the GLP-1 receptor, some of which are used to treat diabetes, include semaglutide (Wegovy and Ozempic), Tirzepatide, Liraglutide and Exenatide (a drug that is now interrupted).
New research, published in EclicalMedicine magazine was presented at the European Congress on Obesity in Malaga.
It has revealed that the first generation of GLP-1 receptor agonist such as Liraglutid and Exenatis may benefit from cancer outside the loss of weight.
First of all, the researchers discovered similar rakes of crabs associated with obesity among patients treated with drugs and those given by bariatric surgery.
Author of the Sumple Leadership, dr. Yael Wolff Sagy from Clalit Health Services in Tel-Aviv, Israel, also stated the “direct effect of GLP-1 agonist receptor” to be 41 percent more efficiently in the prevention of the prevention of cancer overflow. “
She added: “We still don’t understand how GLP-1S is doing, but this study adds growing evidence that shows that only weight loss cannot fully invest metabolic, anti-cancer and many other benefits that provide these medications.”
Being excess or obese second is the biggest cause of cancer in the UK, causing more than one in 20 cases of cancer.
The risk is higher, which are more difficult people and the longer they have been excess weight.
Healthy weight storage reduces the risk of 13 different types of cancer, including breast, hose, pancreas, oeesophageal and gallbladder cancer.
In the new study, researchers analyzed data on the electronic health record for obese people and those with type 2 diabetes, and all without the previous history of cancer, which were treated with the first generation of GLP-1 agonists.
Typical monitoring of 7.5 years, 298 patients were diagnosed with the cancer related to obesity, most common breast, hose and cancer matter.
The analysis found that the cancer was associated with obesities in 150 of 3,178 patients with bariatric surgery and in 148 of 3,178 patients taking GLP-1 bariatric surgery in reducing weight, which is already known to reduce the risk of cancer.
Further analysis suggested in GLP had a direct effect on reducing cancer relating to obesity beyond weight loss, with 41 percent lower relative risk in relation to bariatric surgery.
The author of Suighten, Professor Droor from Hasharon Hospital, the Medical Center Rabbin in Israel, said: “The protective effects of the GLP1-RAS against obesity that relate to obesity is likely to occur from multiple mechanisms, including inflammation.
“Our study is unique that long-term monitoring has enabled you to compare the effects of GLP1-RAS and operations with potential periods of cancer.
“New generation, high-potential GLP1-RAS with greater efficiency in reducing the risks of repetitive pans, but future research is needed to make these medications increase for non-prebibine cancer.”
Supred Sattara, a professor of cardiometabolic medicine at Glasgow University, said higher trials with a careful group of groups of people to test the theory.
“This study, while interesting, cannot confirm or reject some of the cricket therapies with cancer, because the design was not a trial, but was quite significant differences between groups in the basic characteristics,” he said.
“It is better to wait to see further trials with great outcomes compared to placebo to get closer to the truth.”
He said higher interrogations needed to understand the links between such drugs and the risks of cancer, and several should be reported in the next five years. “